UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR Delaware 51-0619477 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) ☒ Yes ☐ ...

FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Second Quarter 2024 Financial Results -- Conference call today at 4:30 p.m. ET -- • EXPAREL net product sales were $136.9 million in the second quarter of 2024, versus $135.1 million reported for the second quarter of 2023. Second quarter volume growth of 3 percent was offset by contracted discounts and vial mix. There were 63 selling days in the second quarter of 2024 and 64 selling days in the second quarter of 2023. • Non-GAAP net income was $ ...

-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2024. Second Quarter 2024 Financial Highlights Total revenues of $178.0 million Net product sales of $136.9 million for EXPAREL, $30.7 million for ZILRETTA, and $5.7 million for iovera° Net income of $18.9 million, or ...

For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira w ...

Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels. One stock to keep an eye on is Pacira BioSciences (PCRX) . PCRX is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the compan ...

The proposed rule is part of the implementation of the Non-Opioids Prevent Addiction in the Nation Act, which requires separate CMS payments for qualifying non-opioid drugs and devices in HOPD and ASC settings. This law was included in the Consolidated Appropriations Act of 2023. To date, Exparel has been used in more than 14 million patients across the United States. The proposed Medicare payment rates for covered non-opioid drug products, as outlined in the rule, will be set at the average sales price plu ...

-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – "Following several years of advocacy for reimbursement policy reform to allow increased patient and provider access to non-opioids, we are pleased to see EXPAREL included as one of only six qualifying non-opioid drugs to treat postsurgical pain in the proposed rule," said Frank D. Lee, Chief Executive ...

The proposed rule reflects impending implementation of the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, which mandates separate CMS payment for qualifying non-opioid drugs and devices across HOPD and ASC settings. The law was passed as part of the Consolidated Appropriations Act of 2023. | --- | --- | |----------------------------------|---------------------------------------------------------| | | | | Non-Opioid Drug | Proposed Separate CMS Payment Rate (Per Billing Unit)* | | EXPAREL | $1.41 ...

It has been about a month since the last earnings report for Pacira (PCRX) . Shares have added about 1.7% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Pacira due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Pacira Q1 Earnings Miss, Exparel Sales Drive Revenues ...

1Q24 Earnings Presentation May 2024 Forward-looking statements and where to find additional information This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentio ...